In vivo, high expression of RNF167 in breast tumors correlates with poor survival in human epidermal growth factor receptor 2 positive (HER2+) breast cancer while lower CASTOR1 expression was correlated with poor survival in estrogen receptor-positive (ER+) breast cancer [81]. Here, ESR1 is linked to breast carcinoma.